Keywords: avastin, proves, disappointing, roche/genetech, studies, asco, gi

Avastin proves disappointing for Roche/Genetech in two studies at ASCO GI

Article | 29 January 2007

Print This

Two Phase III studies presented this month at the American Society of Clinical Oncology's gastro-intestinal meeting in Orlando, Florida, were ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in